Prime Medicine and Beam Therapeutics had common origins in gene editing. Now they're both pursuing treatments for the same ...

News of a fresh investigational program was putting some zip into the shares of gene-editing company Prime Medicine (NASDAQ: ...

Prime Editing has potential to be best-in-class approach for AATD ---- Previously undisclosed program now emerging from within liver platform; ...

The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), ...

Shares of Prime Medicine ( PRME -0.25%) are surging on Thursday. The gene-editing company's stock gained 10.5% as of 2 p.m.

Prime Medicine, Inc. announced the launch of a preclinical program targeting alpha-1 antitrypsin deficiency (AATD), a genetic disorder affecting lung and liver function, utilizing their ...

Acquired DNA mutations found in the SERPINA1 gene can protect liver cells from damage in patients with alpha-1 antitrypsin ...

Korro Bio, Inc. has completed dosing for the first two cohorts in its Phase 1/2a REWRITE clinical study of KRRO-110, aimed at treating Alpha-1 Antitrypsin Deficiency (AATD), with interim results ...

BEAM-302 "has set the bar for efficacy in this space," William Blair analysts wrote in an investor note on Monday.

today unveiled a preclinical program for the treatment of alpha-1 antitrypsin deficiency (AATD), the next program within its liver franchise. Prime Medicine expects to file an investigational new ...

Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim ...

While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...